Skip to main content
CHUGAI PHARMACEUTICAL CO., LTD. logo

CHUGAI PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 4519 ISIN · JP3519400000 LEI · 529900T9LAII161DCN95 T Manufacturing
Open in API
Filings indexed 81 across all filing types
Latest filing 2022-07-22 Interim / Quarterly Rep…
Country JP Japan
Listing T 4519

About CHUGAI PHARMACEUTICAL CO., LTD.

https://www.chugai-pharm.co.jp/english/

Chugai Pharmaceutical Co., Ltd. is a research and development-driven pharmaceutical company dedicated to creating innovative medical products to address unmet medical needs. As a member of the Roche Group, Chugai leverages its advanced expertise in biotechnology and science to develop novel treatments, establishing a leading position in therapeutic antibodies. The company's strategy emphasizes a shift towards discovery research and early clinical development, the integration of digital technologies, and open innovation through external partnerships. Its core therapeutic areas include oncology, rheumatology, and haemophilia, where it provides biopharmaceuticals and molecular targeted therapies to patients.

Recent filings

Filing Released Lang Actions
四半期報告書－第112期第2四半期(令和4年4月1日－令和4年6月30日)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) filed with the Kanto Local Finance Bureau in Japan, as indicated by the header and the regulatory reference (Financial Instruments and Exchange Act). It covers the fiscal period from April 1, 2022, to June 30, 2022. It contains comprehensive financial statements, management analysis (MDA), and operational updates, which fits the definition of an Interim/Quarterly Report (IR). H1 2022
2022-07-22 Japanese
四半期報告書－第112期第1四半期(令和4年1月1日－令和4年3月31日)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Securities Report' (四半期報告書) filed with the Kanto Local Finance Bureau in Japan, covering the first quarter of 2022 (January 1, 2022, to March 31, 2022). It contains detailed financial statements, management analysis (MDA), and operational updates. As it is a comprehensive financial report for a period shorter than a full fiscal year, it falls under the 'Interim / Quarterly Report' category. Q1 2022
2022-04-26 Japanese
確認書
Audit Report / Information Classification · 95% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act in Japan. It serves as a formal certification by the CEO and CFO regarding the accuracy of the company's Annual Securities Report (Yuuka Shouken Houkokusho). Since this is a regulatory filing required by law to accompany or validate financial reporting and does not fit into specific categories like 10-K or IR, it is classified as a Regulatory Filing (RNS). FY 2021
2022-03-30 Japanese
訂正有価証券報告書－第111期(令和3年1月1日－令和3年12月31日)
Annual Report Classification · 100% confidence The document is a Japanese 'Yuka Shoken Hokokusho' (Securities Report), which is the Japanese equivalent of an Annual Report (10-K). It contains comprehensive financial data, business indicators, and management information for the fiscal year 2021 (January 1, 2021, to December 31, 2021). The document structure, including the header and the 'Part 1: Corporate Information' section, confirms it is the full annual filing rather than an announcement or a summary. FY 2021
2022-03-30 Japanese
内部統制報告書－第111期(令和3年1月1日－令和3年12月31日)
Governance Information Classification · 100% confidence The document is an 'Internal Control Report' (内部統制報告書) filed under the Financial Instruments and Exchange Act of Japan. It details the company's framework, scope, and assessment results regarding internal controls over financial reporting. This type of document is a specific regulatory requirement in Japan, often filed alongside or as part of the annual reporting process, and falls under the 'Audit Report / Information' category as it pertains to the assessment of internal controls and audit-related compliance.
2022-03-29 Japanese
確認書
Audit Report / Information Classification · 95% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act, Article 24-4-2, Paragraph 1. This is a standard Japanese regulatory filing that accompanies the Annual Securities Report (Yukashoken Hokokusho) to confirm the accuracy of the report's contents by the CEO and CFO. Since it is a specific regulatory filing required by law and does not fit into the other categories like 10-K or IR, it is classified as a Regulatory Filing (RNS). FY 2021
2022-03-29 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.